EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets

Charlie Leboff iD, Pamela Calle-Mendoza iD, Maria Hatziapostolou iD, Christos Polytarchou iD

British Journal of Pharmacology · 12.08.2026

DOI: 10.1111/bph.70634 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Pharmacology, online erschienen am 12.08.2026. Verfasst von Charlie Leboff und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biosciences, Centre for Systems Health and Integrated Metabolic Research, John van Geest Cancer Research Centre, School of Science and …. Die Arbeit nennt 211 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long non‐coding RNAs (lncRNAs), a broad class of non‐protein‐coding RNAs, are characterized as new regulators of gene expression at the epigenetic, transcriptional, and post‐transcriptional level. Thus, lncRNAs are involved in the regulation of physiological processes and the development of human diseases and cancer by modulating proinflammatory, oncogenic and proangiogenic pathways. Inflammation, cancer and angiogenesis are interlinked through a network of signals and pathways that reinforces itself through feedback loops. Inflammation triggers vessel formation to transfer immune cells and nutrients, and consequently the new vessels enhance the supply of inflammatory cells and factors. Chronic inflammation induces oncogenic transformation and angiogenesis, induced by tumour‐derived signals, support tumour growth and provide the route for distal metastasis. Here we review the implication of lncRNAs in these processes and interactions in the gastrointestinal tract, with a special focus on inflammation and cancer angiogenesis. LncRNAs, due to their highly cell‐, tissue‐ and disease‐specific expression, are attractive targets for the development of novel therapeutics with limited off‐target effects and toxicity. We discuss new discoveries which highlight the value of lncRNA targeting as therapeutic applications, in gastrointestinal inflammation and cancer angiogenesis, and identify gaps in our current knowledge and understanding. We illustrate advancing approaches, their advantages and challenges for the pharmacological targeting of lncRNAs.

Schlagwörter

Stichwörter der Autor:innen

angiogenesiscancergastrointestinal tractinflammationlong non‐coding RNAs

Autor:innen und Institutionen

  • Department of Biosciences, Centre for Systems Health and Integrated Metabolic Research, John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, UK.

ORCID-Profile: Charlie Leboff, Pamela Calle-Mendoza, Maria Hatziapostolou, Christos Polytarchou

Zitieren

APA

Leboff, C., Calle-Mendoza, P., Hatziapostolou, M., & Polytarchou, C. (2026). Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets. British Journal of Pharmacology. https://doi.org/10.1111/bph.70634

Vancouver

Leboff C, Calle-Mendoza P, Hatziapostolou M, Polytarchou C. Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets. British Journal of Pharmacology. 2026. doi:10.1111/bph.70634

BibTeX
@article{Leboff2026,
  author = {Leboff, Charlie and Calle-Mendoza, Pamela and Hatziapostolou, Maria and Polytarchou, Christos},
  title = {Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets},
  journal = {British Journal of Pharmacology},
  year = {2026},
  doi = {10.1111/bph.70634}
}
Kostenlos starten →